Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Diseases

Hematopoietic stem cell transplantation for multiple sclerosis: finding equipoise

Summary:

Hematopoietic stem cell transplantation of multiple sclerosis is rapidly expanding. Success for this approach requires an understanding of the pathophysiology of multiple sclerosis and design of trials that select patients with active inflammatory disease, low disability scores, and avoidance of conditioning agents that may damage neural stem cell compartments or further compromise already injured axons.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.

    Article  CAS  Google Scholar 

  2. De Stefano N, Matthews PM, Fu L et al. Axonal damage correlates with disability in patients with relapsing–remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121 (Part 8): 1469–1477.

    Article  Google Scholar 

  3. Fu L, Matthews PM, De Stefano N et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121 (Part 1): 103–113.

    Article  Google Scholar 

  4. Ferguson B, Matyszak MK, Esiri MM et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120 (Part 3): 393–399.

    Article  Google Scholar 

  5. Oksenberg JR, Hauser SL . Emerging concepts of pathogenesis: relationship to multiple sclerosis therapies. In: Rudick RA, Goodkin DE (eds). Multiple Sclerosis Therapeutics. Martin Dunitz: London, 1999, pp 215–242.

    Google Scholar 

  6. Burt RK, Burns W, Hess A . Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplantation 1995; 16: 1–6.

    CAS  PubMed  Google Scholar 

  7. Burt RK, Traynor AE, Cohen B et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplantation 1998; 21: 537–541.

    Article  CAS  Google Scholar 

  8. Noseworthy JH, Lucchinetti C, Rodriguez M et al. Multiple sclerosis. N Engl J Med 2000; 343: 938–952.

    Article  CAS  Google Scholar 

  9. Weinshenker BG . The natural history of multiple sclerosis: update 1998. Semin Neurol 1998; 18: 301–307.

    Article  CAS  Google Scholar 

  10. Weinshenker BG . The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119–146.

    Article  CAS  Google Scholar 

  11. Weinshenker BG . Natural history of multiple sclerosis. Ann Neurol 1994; 36 (Suppl): S6–S11.

    Article  Google Scholar 

  12. Lassmann H, Raine CS, Antel J et al. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998; 86: 213–217.

    Article  CAS  Google Scholar 

  13. Jersild C, Fog T, Hansen GS et al. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2: 1221–1225.

    Article  CAS  Google Scholar 

  14. Glabinski AR, Tani M, Tuohy VK et al. Murine experimental autoimmune encephalomyelitis: a model of immune-mediated inflammation and multiple sclerosis. Methods Enzymol 1997; 288: 182–190.

    Article  CAS  Google Scholar 

  15. Paty DW, Li DK, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662–667.

    Article  CAS  Google Scholar 

  16. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon (beta)-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–1285.

  17. PRISMS (Prevention of Relapses and Disability by Interferon (beta)-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon (beta)-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–1504. (Erratum, Lancet 1999; 353: 678.)

  18. European Study Group on Interferon (beta)-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon (beta)-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–1497.

  19. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–661.

  20. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45: 1268–1276.

    Article  CAS  Google Scholar 

  21. Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998; 50: 701–708.

    Article  CAS  Google Scholar 

  22. Millefiorini E, Gasperini C, Pozzilli C et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997; 244: 153–159.

    Article  CAS  Google Scholar 

  23. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112–118.

    Article  CAS  Google Scholar 

  24. Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505–3514.

    CAS  Google Scholar 

  25. Openshaw H, Stuve O, Antel JP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147–2150.

    Article  CAS  Google Scholar 

  26. Openshaw H, Lund BT, Kashyap A et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplantation 2000; 6: 563–575.

    Article  CAS  Google Scholar 

  27. Nash RA, Kraft GH, Bowen JD et al. Treatment of severe multiple sclerosis (MS) with high dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT) (abst 3640). Blood 2000; 96 (Suppl A): 842a.

    Google Scholar 

  28. Nash RA, Dansey R, Storek J et al. Epstein Barr virus (BBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases (abst 1747). Blood 2000; 96 (suppl A): 406a.

    Google Scholar 

  29. Fassas A, Anagnostopoulos A, Kazis A et al. Autologous stem cell transplantation in progressive multiple sclerosis – an interim analysis of efficacy. J Clin Immunol 2000; 20: 24–30.

    Article  CAS  Google Scholar 

  30. Mandalfino P, Rice G, Smith A et al. Bone marrow transplantation in multiple sclerosis. J Neurol 2000; 247: 691–695.

    Article  CAS  Google Scholar 

  31. Carreras E, Saiz A, Graus F et al. Autologous CD34+ selected hematopoietic stem cell transplantation (CD34+/HSCT) for multiple sclerosis: update of a single center experience in 10 patients. Biol Blood Marrow Transplantation (abstr) 2001; 7: 69.

    Google Scholar 

  32. Kozak T, Havrdova E, Pit'ha J et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplantation 2000; 25: 525–531.

    Article  CAS  Google Scholar 

  33. Confavreux C, Vukusic S, Moreau T et al. Relapses and progression of disability in multiple sclerosis. N Eng J Med 2000; 343: 1430–1438.

    Article  CAS  Google Scholar 

  34. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R K Burt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burt, R., Kozak, T. Hematopoietic stem cell transplantation for multiple sclerosis: finding equipoise. Bone Marrow Transplant 32 (Suppl 1), S45–S48 (2003). https://doi.org/10.1038/sj.bmt.1703942

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703942

Keywords

Search

Quick links